The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

GALDY FINANCIAL STATEMENTS

GALDERMA GROUP AG — balance sheet, income statement and cash flow trends

GALDYGALDERMA GROUP AG

🇺🇸 USA · US · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values

Profit Funnel

Q2 2025 · TTM

Key Figures

YoY change
Revenue——
Gross Profit——
Operating Income——
EBITDA——
Net Income to Owners——

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
05 B10 B202320242025

Capital Structure

Q2 2025
Total Assets13.4 B
  • Equity8.2 B $61%
  • Current Liabilities2.1 B $15%
  • Long-term Liabilities3.2 B $24%

Key Figures

YoY change
Total Assets13.4 B $+7.4%
Total Liabilities5.2 B $-26.2%
Total Equity8.2 B $+51.8%
Cash & ST Investments——
Total Debt——
Net Debt1.8 B $-58.7%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Cash Flow Bridge

Q2 2025 · TTM

Key Figures

YoY change
Operating Cash Flow——
Capital Expenditures——
Free Cash Flow——
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on GALDY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.